Ledger. Australian venture funding, tracked

Government · 5 deals

U.S. Department of Defense

Coverage

Stories naming U.S. Department of Defense. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

4 deals

Crunchbase Predicts: 15 Companies That Could Go Public In 2026 As The IPO Market Gains Momentum

Crunchbase's 2026 forecast lists fifteen late-stage companies it deems probable or very likely IPO candidates, profiling each with past raises, valuations and secondary sales; Australia's Canva makes the list.

2 deals

ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

Melbourne pharmaceutical company ENA Respiratory has received US$5 million from California's Flu Lab to advance clinical testing of its nasal immune-boosting antiviral candidate INNA-051.

Also Brandon Capital portfolio

3 deals

ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral

Melbourne's ENA Respiratory has won a further US$3.18 million US Defense Department contract to widen its INNA-051 Phase Ib trial to younger adults, extending the US$8.18 million the agency had already committed.

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·enarespiratory.com

Grant US$4.4m

ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051

ENA Respiratory receives a USD 4.38 million U.S. Department of Defense agreement to develop an intranasal dry powder antiviral; its past Series A backers are also recalled.

Also Brandon Capital portfolio

Something wrong? Tell us